Advertisement
Organisation › Details
Themis Bioscience N.V.
Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for the current vaccine candidates of the Vienna-based company. *
Start | 2009-09-01 established | |
Industry | vaccine | |
Region | Amsterdam | |
Country | Netherlands | |
City | n. a. Amsterdam | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2018-10-29) |
Currency | EUR | |
Annual sales | 2,567,000 (income, operating, other, consolidated (2017) 2017-12-31) | |
Profit | -4,865,000 (2017-12-31) | |
Cash | 5,178,000 (2018-06-30) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Merck (US) (MSD) (Group)
- [1] Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg....
- [2] Biognosys AG. (6/17/20). "Press Release: Biognosys Announces Appointment of Dr. Patrick Vink as Chairman". Schlieren....
- [3] iTeos Therapeutics S.A.. (12/12/19). "Press Release: iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with Keytruda". Gosselies & Cambridge, MA....
- [4] Themis Bioscience GmbH. (10/29/19). "Press Release: Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine". Vienna & Oslo....
- [5] Themis Bioscience N.V.. (11/8/18). "Press Release: Themis Bioscience Postpones Its Listing on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
- [6] Themis Bioscience N.V.. (10/29/18). "Press Release: Themis Bioscience Launches its Initial Public Offering on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
- [7] Noxxon Pharma N.V.. (6/15/18). "Press Release: Noxxon Announces that It Has Secured Additional Financing". Berlin....
- [8] Noxxon Pharma N.V.. (9/28/17). "Press Release: Noxxon Provides Update on Ongoing Phase 1/2 Clinical Trial with Lead Program NOX-A12". Berlin....
- [9] Merck & Co., Inc.. (9/6/17). "Press Release: Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology". Kenilworth, NJ & Munich....
- [10] Complix N.V.. (7/27/17). "Press Release: Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies". Hasselt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top